See more : Frontier Transport Holdings Limited (FTH.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Nexalin Technology, Inc. (NXL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nexalin Technology, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Regency Ceramics Limited (REGENCERAM.BO) Income Statement Analysis – Financial Results
- Endeavor Bancorp (EDVR) Income Statement Analysis – Financial Results
- Prudential plc (PRU.DE) Income Statement Analysis – Financial Results
- ReNeuron Group plc (RNUGF) Income Statement Analysis – Financial Results
- Citiport Financial Services Limited (CITIPOR.BO) Income Statement Analysis – Financial Results
Nexalin Technology, Inc. (NXL)
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 110.75K | 1.32M | 144.07K | 242.91K | 207.38K |
| Cost of Revenue | 25.69K | 363.21K | 21.44K | 29.04K | 218.21K |
| Gross Profit | 85.06K | 958.15K | 122.62K | 213.88K | -10.83K |
| Gross Profit Ratio | 76.80% | 72.51% | 85.12% | 88.05% | -5.22% |
| Research & Development | 1.92M | 511.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 5.78M | 2.79M | 6.14M | 3.47M | 78.13K |
| Selling & Marketing | 0.00 | 886.41K | 35.49K | 10.71K | 1.38M |
| SG&A | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Other Expenses | 0.00 | 171.68K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Cost & Expenses | 5.81M | 3.15M | 6.16M | 3.50M | 1.67M |
| Interest Income | 0.00 | 59.38K | 82.32K | 78.68K | 80.99K |
| Interest Expense | 38.84K | 59.38K | 82.32K | 78.68K | 80.99K |
| Depreciation & Amortization | 4.25K | 5.72K | 537.00 | 429.00 | 535.00 |
| EBITDA | -5.69M | -1.83M | -6.00M | -3.32M | -1.47M |
| EBITDA Ratio | -5,139.63% | -125.69% | -4,177.33% | -1,341.21% | -706.72% |
| Operating Income | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Operating Income Ratio | -5,143.48% | -138.72% | -4,177.70% | -1,341.38% | -706.98% |
| Total Other Income/Expenses | 1.05M | 135.22K | -59.40K | -145.08K | -3.56M |
| Income Before Tax | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Income Before Tax Ratio | -4,197.56% | -128.49% | -4,218.93% | -1,401.11% | -2,421.22% |
| Income Tax Expense | 0.00 | 228.00K | 82.32K | 78.68K | 5.00 |
| Net Income | -4.65M | -1.93M | -6.16M | -3.48M | -5.02M |
| Net Income Ratio | -4,197.56% | -145.75% | -4,276.07% | -1,433.50% | -2,421.22% |
| EPS | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| EPS Diluted | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
| Weighted Avg Shares Out (Dil) | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week
Source: https://incomestatements.info
Category: Stock Reports